Cetuximab

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Cetuximab (ncit:C1723)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
Sensitivity (+) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
Sensitivity (+) EGFR positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan